慢性髓细胞性白血病病程进展中调节蛋白c-Myc、Bcl-2及Fas的表达变化  

Expression of c Myc, Bcl 2 and Fas proteins in different stages of chronic myelocytic leukemia

作　　者：秦亚溱[1] 高晖[1] 陈珊珊[1] 

机构地区：[1]北京医科大学附属人民医院血液病研究所

出　　处：《中华内科杂志》1998年第2期119-121,共3页Chinese Journal of Internal Medicine

摘　　要：目的了解细胞程序死亡（ＰＣＤ）与慢性髓细胞性白血病（ＣＭＬ）急变的关系。方法采用流式细胞术，测定２１例ＣＭＬ及１２例正常骨髓标本单个核细胞的髓系免疫表型及三种与ＰＣＤ有关的调节蛋白——ｃ－Ｍｙｃ、Ｂｃｌ－２、Ｆａｓ的表达。结果与未治慢性期比较，加速／急变期膜抗原最显著的变化是ＨＬＡ－ＤＲ＋％的提高，ＣＤ＋１５％／ＨＬＡ－ＤＲ＋％比值倒置。正常骨髓及ＣＭＬ各期ＨＬＡ－ＤＲ＋及ＨＬＡ－ＤＲ－细胞几乎均表达ｃ－Ｍｙｃ，差别只在于表达量的多少，未治慢性期与正常骨髓组相似，加速／急变期组不仅显著高于未治慢性期组，其ＨＬＡ－ＤＲ＋细胞群的ｃ－Ｍｙｃ表达量亦显著高于正常骨髓组。Ｂｃｌ－２＋％在未治慢性期低于正常骨髓，加速／急变期组显著提高。Ｆａｓ在ＣＭＬ各期及正常骨髓均为低表达。结论处于未治慢性期的中、晚幼粒细胞的大量聚集似乎与Ｂｃｌ－２、Ｆａｓ的ＰＣＤ调节作用无关；而在加速／急变期组尤其是造血祖细胞不仅有增殖过旺。Objective To investigate the association of the programmed cell death (PCD) regulating proteins with the acute transformation of chronic myelogenous leukemia (CML). Methods We detected c Myc, Bcl 2 and Fas proteins and performed immunophenotyping by flow cytometry in 21 cases of CML marrows and 9 normal bone marrows (NBM). Results Compared to NBM and untreated chronic phase (UT CP), marrows from accelerate phase/blastic crisis (AP/BC) had an increasing percentage of HLA DR + cells and the ratio of CD + 15 %/HLA DR +% was below 1.0. c Myc protein was expressed on almost all of the HLA DR + and HLA DR - cells from NBM and CML marrow, but there was difference in quantity as measured by fluorescent intensity. The quantity of c Myc protein expression in HLA DR + cells from AP/BC marrow increased significantly, while that from in UT CP and NBM was at a low level. The percentage of Bcl 2 + cells in AP/BC marrow was the highest and it was lower in UT CP than that in NBM. Fas +% was quite low in all CML and NBM samples without statistical difference. Conclusion We assume that Bcl 2 and c Myc protein may be involved in PCD inhibition and malignant proliferation of hematopoietic progenitors in AP/BC, but the accummulation of myeloid lineage cells in UT CP may not be related to the PCD regulating proteins we tested.

关 键 词：白血病 髓样 慢性 脱噬作用 调节蛋白 

分 类 号：R733.720.2[医药卫生—肿瘤]